Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | TPH1 | P17752 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15469207 | 1.00 | HSD17B10 (0.47) | HSD17B10SLC7A5PTGS1PKMALPI | |
| SCHEMBL29373039 | 0.90 | SLC7A5 (0.41) | HSD17B10SLC7A5PTGS1PKMALPI | |
| SCHEMBL15469201 | 0.90 | SLC7A5 (0.41) | HSD17B10SLC7A5PTGS1PKMALPI | |
| SCHEMBL15511517 | 0.90 | SLC7A5 (0.41) | HSD17B10SLC7A5PTGS1PKMALPI | |
| SCHEMBL17814914 | 0.82 | SLC7A5 (0.57) | HSD17B10SLC7A5PTGS1PKMALPI | |
| SCHEMBL15469220 | 0.82 | SLC7A5 (0.57) | HSD17B10SLC7A5PTGS1PKMALPI | |
| SCHEMBL24248048 | 0.79 | HSD17B10 (0.55) | HSD17B10SLC7A5PTGS1PKMALPI | |
| SCHEMBL18995731 | 0.79 | HSD17B10 (0.55) | HSD17B10SLC7A5PTGS1PKMALPI | |
| SCHEMBL15495954 | 0.79 | HSD17B10 (0.55) | HSD17B10SLC7A5PTGS1PKMALPI | |
| SCHEMBL19198746 | 0.77 | HSD17B10 (0.54) | HSD17B10SLC7A5PTGS1PKMALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025076210-A1 | CHLAMYDIA VACCINE COMPOSITIONS | VAXCYTE, INC. (US) | 2025-04-10 | — | — | WO | claimed |
| US-20240358823-A1 | CONJUGATED VACCINE CARRIER PROTEINS | VAXCYTE, INC. | 2024-10-31 | — | — | US | claimed |
| US-20240335521-A1 | STABILIZATION OF ADJUVANTED VACCINE COMPOSITIONS AND THEIR USE | VAXCYTE, INC. | 2024-10-10 | — | — | US | claimed |
| CN-118662649-A | Polypeptide-antigen conjugates with unnatural amino acids | VAXCYTE公司 | 2024-09-20 | — | — | CN | claimed |
| EP-4395818-A1 | STABILIZATION OF ADJUVANTED VACCINE COMPOSITIONS AND THEIR USE | VAXCYTE, INC. (US) | 2024-07-10 | — | — | EP | claimed |
| CN-117479961-A | Purification method of polysaccharide and polypeptide conjugate thereof | VAXCYTE公司 | 2024-01-30 | — | — | CN | claimed |
| US-20240000926-A1 | PURIFICATION PROCESSES FOR POLYSACCHARIDES AND POLYPEPTIDE CONJUGATES THEREOF | VAXCYTE, INC. | 2024-01-04 | — | — | US | claimed |
| EP-4294452-A1 | PURIFICATION PROCESSES FOR POLYSACCHARIDES AND POLYPEPTIDE CONJUGATES THEREOF | VAXCYTE, INC. (US) | 2023-12-27 | — | — | EP | claimed |
| US-20230293658-A1 | GROUP A STREP IMMUNOGENIC COMPOSITIONS WITH POLYSACCHARIDE-PROTEIN CONJUGATES | VAXCYTE, INC. | 2023-09-21 | — | — | US | claimed |
| WO-2023034932-A1 | STABILIZATION OF ADJUVANTED VACCINE COMPOSITIONS AND THEIR USE | VAXCYTE, INC. (US) | 2023-03-09 | — | — | WO | claimed |
| US-20220125907-A1 | OPTIMIZED CELL-FREE SYNTHESIS OF INVASION PLASMID ANTIGEN B AND RELATED COMPOSITIONS AND METHODS OF USE | VAXCYTE, INC. | 2022-04-28 | — | — | US | claimed |
| EP-3946443-A1 | OPTIMIZED CELL-FREE SYNTHESIS OF INVASION PLASMID ANTIGEN B AND RELATED COMPOSITIONS AND METHODS OF USE | VAXCYTE, INC. (US) | 2022-02-09 | — | — | EP | claimed |
| CN-114025789-A | Optimized cell-free synthesis of invasive plasmid antigen B and related compositions and methods of use | VAXCYTE公司 | 2022-02-08 | — | — | CN | claimed |
| WO-2020205584-A1 | OPTIMIZED CELL-FREE SYNTHESIS OF INVASION PLASMID ANTIGEN B AND RELATED COMPOSITIONS AND METHODS OF USE | VAXCYTE, INC. (US) | 2020-10-08 | — | — | WO | claimed |
| US-20200054739-A1 | CONJUGATED VACCINES | SUTROVAX, INC. | 2020-02-20 | — | — | US | claimed |
| EP-3562503-A2 | POLYPEPTIDE-ANTIGEN CONJUGATES WITH NON-NATURAL AMINO ACIDS | Sutrovax, Inc. (US) | 2019-11-06 | — | — | EP | claimed |
| CN-110366428-A | Polypeptide-antigen conjugates with unnatural amino acids | SUTROVAX公司 | 2019-10-22 | — | — | CN | claimed |
| WO-2018126229-A9 | POLYPEPTIDE-ANTIGEN CONJUGATES WITH NON-NATURAL AMINO ACIDS | SUTROVAX, INC. (US) | 2019-07-25 | — | — | WO | claimed |
| US-20180333484-A1 | Polypeptide-Antigen Conjugates with Non-Natural Amino Acids | SUTROVAX, INC. (US) | 2018-11-22 | — | — | US | claimed |
| WO-2018126229-A2 | POLYPEPTIDE-ANTIGEN CONJUGATES WITH NON-NATURAL AMINO ACIDS | SUTROVAX, INC. (US) | 2018-07-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240000926-A1 | PURIFICATION PROCESSES FOR POLYSACCHARIDES AND POLYPEPTIDE CONJUGATES THEREOF | DDOST, ALG1, PAG1 | HSD17B10 3804/4885SLC7A5 2269/4885PTGS1 3725/4885 |
| US-20200054739-A1 | CONJUGATED VACCINES | ASNS, CD14, CD74 | HSD17B10 2068/4885SLC7A5 129/4885PTGS1 3300/4885 |
| US-20180333484-A1 | Polypeptide-Antigen Conjugates with Non-Natural Amino Acids | CD74, DNPEP, NGLY1 | HSD17B10 3231/4885SLC7A5 227/4885PTGS1 3633/4885 |
| US-20240358823-A1 | CONJUGATED VACCINE CARRIER PROTEINS | CD74, LY96, ASNS | HSD17B10 2269/4885SLC7A5 91/4885PTGS1 3185/4885 |
| US-20230293658-A1 | GROUP A STREP IMMUNOGENIC COMPOSITIONS WITH POLYSACCHARIDE-PROTEIN CONJUGATES | SIGLEC9, SIGLEC7, CD14 | HSD17B10 4067/4885SLC7A5 2763/4885PTGS1 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.